Aerska
Developing RNA medicines to treat, delay, and prevent diseases of the brain.
Aerska is developing systemically administered RNA interference (RNAi) medicines for diseases of the brain by leveraging an antibody-oligonucleotide conjugate platform with “brain-shuttle” delivery to cross the blood-brain barrier.
Founders
Jack O'Meara
Cofounder
Jack is a biomedical engineer by training, with a background in bringing new technologies to market. He holds a First Class degree from the University of Galway and a Master’s from Notre Dame in Engineering & Science. He helped to see one of the first blockbuster gene therapies through FDA approval and onto commercial launch.